Mesothelioma.com Resources for Patients and their Families

Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma

Brief Summary

The aim is to introduce a new therapeutic method of intracavitary chemotherapy (cisplatin) combined with a fibrin carrier (Vivostat®) after pleurectomy/decortication or extrapleural pneumonectomy in a phase I and II study for Malignant Pleural Mesothelioma patients by evaluation of the safety in a dose-escalating model (phase I), and confirmation of safety and efficacy in phase II with the maximum tolerated dose in phase I.

Tracking Information
First Received DateJuly 17, 2012
Last Changed DateAugust 22, 2017
Start DateNovember 2012
Anticipated Primary Completion DateAugust 2020
Primary Outcome Measures

Incidence of Treatment-Emergent Adverse Events (Safety) [Time Frame: during 6 weeks after surgery with local cisplatin-fibrin application]

Cisplatin concentration in the superficial chest wall tissue [Time Frame: 90 min after application]

Secondary Outcome Measures

overall survival [Time Frame: up to 5 years (phase I), up to 2 years (phase II)]

FFR (= Freedom From Recurrence) [Time Frame: 4, 16 weeks, then every 4 months up to 5 (phase I) / 2 years (phase II)]

in-treatment-field FFR (= Freedom From Recurrence) [Time Frame: up to 2 years (phase II)]

Quality of Life SF-36 (= Short Form-36) [Time Frame: phase I: 0, 4, 8, 16 weeks and every 4w up to 5y; phase II: 0, 6, 16w and every 4w up to 2y]

Quality of Life EORTC QLQ-C15/LC13 (QLQ = Quality of Life Questionnaire, C = Cancer, LC = Lung Cancer) [Time Frame: phase I: 0, 4, 8, 16 weeks and every 4w up to 5y; phase II: 0, 6, 16w and every 4w up to 2y]

pharmacokinetics cisplatin concentration in blood serum [Time Frame: baseline, and 0, 2, 6, 10, 24, 48, 120 h postoperative]

pharmacokinetics cisplatin concentration in urine [Time Frame: baseline, collection of first 48h, day 14 postoperative]

TUNEL assay [Time Frame: before and 90 min after cisplatin-fibrin application]

PAI-1 and p21 (PAI-1 = Plasminogen Activator Inhibitor Typ 1, p21 = CDK-Inhibitor 1 = Cyclin Dependent Kinase Inhibitor 1)) [Time Frame: before and 90 min after cisplatin-fibrin application]

Descriptive Information
PhasePhase 1/Phase 2
Study TypeInterventional
Condition
  • Malignant Pleural Mesothelioma
Intervention
  • Combination Product: intracavitary cisplatin-fibrin
Study Arms / Comparison Groups1 / 0
Recruitment Information
Recruitment StatusRecruiting
Anticipated Enrollment54
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Contact Isabelle Opitz, Professor MD
Email: isabelle.schmitt-opitz@usz.ch
Phone: +41 (0)44 255 11 11
Eligibility Criteria

Inclusion criteria:

- Patient is able to understand and willing to sign a written informed consent document.

- Male or female, age >=18 years

- ECOG performance status =<2 (ECOG = Eastern Cooperative Oncology Group)

- Resectable MPM (Malignant Pleural Mesothelioma) histologically confirmed (phase I: stage cT1-cT4 cN0-cN3 cM0-cM1 / phase II: stage cT1-cT3 cN0-cN1 cM0) (TNM Tumor staging abbreviations: c = clinical; T = Tumor, N = lymph Nodes, M = Metastases; numbers = quantity)

- Only Phase II: Mediastinal staging (cytological or histological)

- Only Phase II: Induction chemotherapy (3 or more cycles cisplatin or carboplatin (also in combination with other therapeutic agents)

- Patient qualifying for (extended) pleurectomy/decortication ((e)P/D) or extrapleural pneumonectomy (EPP) for resection of MPM, which has to be assessed during a multidisciplinary tumor board including a thoracic surgeon

- Patient must have appropriate organ and bone marrow function as defined: hematologic function: hemoglobin ≥100 g/L, WBC (white blood cell count) ≥3.5 G/L, neutrophils ≥1.5 G/L, thrombocytes ≥100 G/L; liver function: total bilirubin and LDH (lactate dehydrogenase) ≤1.5 x ULN (upper limit of normal); AST (aspartate aminotransferase), ALT (alanine aminotransferase), GGT (gamma glutamyltransferase), and AP (alkaline phosphatase) ≤2.5 x ULN; renal function: creatinine ≤130 μmol/L or, if greater, creatinine clearance ≥60 ml/min/1.73m2.

- Patient must have an appropriate blood coagulation for P/D or EPP (Quick-test > 50%, INR (international normalized ratio) <=1.2)

- The patient agrees to use an efficient contraceptive treatment up to 3 months after cisplatin application if required (pre-menopausal women and men in a sexually mature age).

- Heart and lung function allowing P/D under general anesthesia

Exclusion criteria:

- Known or suspected unwillingness of the patient to follow the rules of the protocol

- Patient who has not recovered from side effects from prior chemotherapy or radiotherapy.

- Any known hypersensitivity against cisplatin or other platinum containing substances or any other components used for the preparation of the drugs.

- Patient must not receive any other investigational agents 4 weeks before treatment and until the end of the observation period (2 months after treatment).

- Patient with prior ipsilateral pleurectomy

- Only Phase II: Multimodality Prognostic Score (MMPS) > 2:

4 items with a maximum possible score of 4 if the patient presented all four conditions and 0 if none were present: Tumor volume before induction chemotherapy > 500 ml, non-epithelioid histotype in the diagnostic biopsy before induction chemotherapy, CRP (C reactive protein) value > 30 mg/l before induction chemotherapy, and progressive disease after induction chemotherapy according to RECIST criteria

- Patient with uncontrolled intercurrent illnesses that would limit the operative procedure of P/D / EPP or compliance with study requirements

- Tinnitus impairment of more than severity grade I (slight) evaluated by the tinnitus questionnaire MiniTF12_CH (Mini Tinnitus Fragebogen 12, CH = Confoederatio Helvetica (Swiss version)), and/or restricted power of hearing until 4 kHz (kilohertz) confirmed by audiometry, unless age-related presbyacusis in a normal range confirmed by an audiologist.

- Known alcohol and/or drug abuse at the time of screening

- Pregnant or lactating woman

Administrative Information
NCTIDNCT01644994
Responsible Party,
SponsorUniversity of Zurich
Verification DateAugust 2017
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

How Brazil’s Asbestos Ban Impacts the Rest of the World

Jenni DeHart Remembers Her Father’s Battle with Stage 4 Pleural Mesothelioma

Talcum Powder Lawsuits: How Asbestos-Contaminated Talc Harms People

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: